|
CD14
|
SD
|
CD68
|
SD
|
GAPDH
|
SD
|
---|
Day 2
| | | | | | |
---|
+ E2
|
No CT
| |
No CT
| |
22.28
|
0.26
|
+ Macrophages
|
23.88
|
0.10
|
28.18
|
0.24
|
21.59
|
0.24
|
+ E2 and Macrophages
|
26.36
|
0.16
|
28.52
|
1.50
|
22.69
|
0.23
|
Day 6
| | | | | | |
+ E2
|
No CT
| |
No CT
| |
22.48
|
0.31
|
+ Macrophages
|
28.37
|
3.40
|
30.02 a
|
1.39
|
20.88
|
0.70
|
+ E2 and Macrophages
|
27.65
|
4.92
|
30.01a
|
3.57
|
19.69
|
0.91
|
Day 10
| | | | | | |
+ E2
|
No CT
| |
No CT
| |
19.16
|
0.33
|
+ Macrophages
|
31.05a
|
0.81
|
30.81a
|
1.55
|
18.51
|
0.15
|
+ E2 and Macrophages
|
29.43
|
1.51
|
31.28 a
|
1.12
|
18.65
|
1.13
|
Controls
| | | | | | |
Human monocytes
|
14.4
|
0.14
|
16.3
|
0.16
|
20.59
|
0.07
|
Human macrophages
|
16.5
|
0.16
|
20.2
|
0.09
|
21.00
|
0.20
|
Murine mammary gland
|
No CT
| |
No CT
| |
21.45
|
0.14
|
- aCycle Threshold (CT) values over 30 were not considered positive for a detectable signal. Analysis was terminated at 32 cycles. E2, ectopic estradiol treatment; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.